Want to see RPRX full AI Analyst Report?
RPRX Stock Chart & Stats
$58.83
-$0.19(-0.32%)
At close: 4:00 PM EDT
$58.83
-$0.19(-0.32%)
Day’s Range― - ―
52-Week Range$34.08 - $60.44
Previous CloseN/A
Volume2.11M
Average Volume (3M)3.18M
Market Cap
$33.70B
Enterprise Value$42.30K
Total Cash (Recent Filing)$836.99M
Total Debt (Recent Filing)$8.96B
Price to Earnings (P/E)24.7
Beta0.17
Next Earnings
Nov 11, 2026EPS Estimate
1.17Next Dividend Ex-DateN/A
Dividend Yield1.56%
Share Statistics
EPS (TTM)2.41
Shares Outstanding445,277,340
10 Day Avg. Volume2,718,135
30 Day Avg. Volume3,176,121
Financial Highlights & Ratios
PEG Ratio0.78
Price to Book (P/B)2.58
Price to Sales (P/S)7.02
P/FCF Ratio6.70
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$65.67Price Target Upside11.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)5.31
Revenue Forecast (FY)$3.49B
Bulls Say, Bears Say
Bulls Say
Very Strong Cash Generation And ConversionRoyalty Pharma’s operating cash flow and free cash flow are large and growing, with operating cash well above net income and ~95% cash conversion. This durable cash generation supports debt servicing, repeat acquisitions, and shareholder returns, underpinning capital allocation flexibility over years.
Expanded Development Pipeline And Strategic Cliramitug DealRoyalty Pharma’s move into late‑stage development with a larger, diversified pipeline (now 19 assets) plus the cliramitug royalty creates future high‑leverage payoffs if trials succeed. A broader deal flow reduces single‑asset concentration and supports multi‑year royalty receipt growth when approvals occur.
Improved Liquidity And Credit ProfileA new $1.8B revolver plus an investment‑grade upgrade enhance structural liquidity and funding optionality for acquisitions. Better access to committed capital and improved credit standing lowers refinancing risk and supports disciplined, long‑term capital deployment into royalty investments.
Bears Say
Material And Rising LeverageRoyalty Pharma’s meaningful debt load and upward leverage trend reduce financial flexibility if portfolio receipts falter. High absolute debt requires sustained cash conversion to meet interest and covenant tests, increasing vulnerability to cyclical or product‑specific revenue disruptions over a multi‑quarter horizon.
Dependence On Late‑stage Clinical OutcomesA growing portion of prospective returns is tied to development‑stage assets that require successful pivotal trials. If late‑stage readouts are delayed or fail, expected future royalty streams and projected IRRs could be materially reduced, making near‑term growth contingent on binary clinical outcomes.
One‑time Milestone Declines And Structural Product HeadwindsExpected drops in milestone receipts and identifiable product pressures (loss of exclusivity, biosimilar entry, policy changes) create persistent revenue risk for certain portfolio components. These structural headwinds complicate predictability of receipts and require more acquisitions or organic growth to sustain long‑term revenue trends.
Royalty Pharma News
RPRX FAQ
What was Royalty Pharma PLC’s price range in the past 12 months?
Royalty Pharma PLC lowest stock price was $34.08 and its highest was $60.44 in the past 12 months.
What is Royalty Pharma PLC’s market cap?
Royalty Pharma PLC’s market cap is $33.70B.
When is Royalty Pharma PLC’s upcoming earnings report date?
Royalty Pharma PLC’s upcoming earnings report date is Nov 11, 2026 which is in 85 days.
How were Royalty Pharma PLC’s earnings last quarter?
Royalty Pharma PLC released its earnings results on Aug 05, 2026. The company reported $1.321 earnings per share for the quarter, beating the consensus estimate of $1.273 by $0.048.
Is Royalty Pharma PLC overvalued?
According to Wall Street analysts Royalty Pharma PLC’s price is currently Undervalued.
Does Royalty Pharma PLC pay dividends?
Royalty Pharma PLC pays a Quarterly dividend of $0.235 which represents an annual dividend yield of 1.56%. See more information on Royalty Pharma PLC dividends here
What is Royalty Pharma PLC’s EPS estimate?
Royalty Pharma PLC’s EPS estimate is 1.17.
How many shares outstanding does Royalty Pharma PLC have?
Royalty Pharma PLC has 445,277,340 shares outstanding.
What happened to Royalty Pharma PLC’s price movement after its last earnings report?
Royalty Pharma PLC reported an EPS of $1.321 in its last earnings report, beating expectations of $1.273. Following the earnings report the stock price went up 0.47%.
Which hedge fund is a major shareholder of Royalty Pharma PLC?
Currently, no hedge funds are holding shares in RPRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Royalty Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$65.67 (11.62% Upside)
$65.67 (11.62% Upside)
Blogger Sentiment
Neutral
RPRX Sentiment 60%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 469.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
64.23%
12-Months-Change
Fundamentals
Return on Equity
1.56%
Trailing 12-Months
Asset Growth
8.17%
Trailing 12-Months
Company Description
Royalty Pharma PLC
Royalty Pharma plc (RPRX) is a biopharmaceutical royalty company that acquires and manages a portfolio of royalty and related interests in revenue-generating biopharmaceutical products and late-stage development programs. The company operates in the life sciences/healthcare sector and provides capital to drug developers (including biopharmaceutical companies, academic institutions, hospitals, and research organizations) in exchange for future cash flows tied to product sales, milestones, or other drug-related payments.
RPRX Company Deck
RPRX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized multiple strong positives: double‑digit recurring cash flow growth, raised full‑year guidance, disciplined capital deployment (including a strategic cliramitug purchase), expanded development‑stage pipeline with high historical success rates, robust cash generation, and an investment‑grade credit upgrade. Lowlights were present but largely manageable: a material decline in milestone/contract receipts (one‑time prior period effect), specific product headwinds (Promacta, biosimilar Tysabri, IRA), dependence on future pivotal trial outcomes for some investments, modestly higher expected operating expense rates in H2, and geopolitical/regulatory uncertainty in China. Overall, the positives—strong growth, improved guidance, financial flexibility, and portfolio expansion—substantially outweigh the risks and near‑term headwinds.View all RPRX earnings summariesRPRX Revenue Breakdown
93.34% Income from financial royalty assets
6.62% Other royalty income
0.04% Revenue from intangible royalty assets
RPRX Stock 12 Month Forecast
Average Price Target
$65.67
▲(11.62% Upside)
Technical Analysis
Ownership Overview
1.52% Insiders
19.23% Mutual Funds
25.90% Other Institutional Investors
42.09% Public Companies and Individual Investors